L7076 Antibody

What is the L7076 antibody and what are its primary applications?

The L7076 antibody is an affinity-purified horse anti-mouse IgG (heavy and light chain) antibody conjugated to horseradish peroxidase (HRP) primarily used for secondary detection in Western blotting applications . This antibody specifically recognizes mouse immunoglobulins and is optimized for chemiluminescent detection systems. Unlike primary antibodies that directly target antigens of interest, L7076 functions as a secondary detection tool that binds to primary antibodies of mouse origin, enabling visualization through its conjugated HRP enzyme.

The recommended working dilutions for L7076 vary based on the detection reagent used:

• For LumiGLO Reagent and Peroxide: 1:1,000-1:3,000

• For SignalFire ECL Reagent: 1:1,000-1:3,000

• For SignalFire Plus ECL Reagent: 1:5,000-1:15,000

• For SignalFire Elite ECL Reagent: 1:10,000-1:20,000

These dilution ranges have been experimentally validated to provide optimal signal-to-noise ratios across various detection systems.

How should researchers validate the specificity of L7076 antibody in their experimental systems?

Validation of L7076 specificity should follow a systematic approach that addresses both general antibody validation principles and application-specific considerations:

• Cross-reactivity assessment: Though L7076 is designed to bind mouse IgG specifically, researchers should perform control experiments with non-mouse primary antibodies to confirm absence of non-specific binding.

• Secondary-only controls: Always include control samples treated only with L7076 (without primary antibody) to identify potential direct binding to endogenous proteins.

• Target-specific validation: For each new primary antibody paired with L7076, validation should include:

  • Positive and negative control samples with known target expression

  • Comparison with alternative detection methods

  • Assessment of signal intensity correlation with expected target abundance

• Context-dependent validation: As emphasized by The Antibody Society, verification must focus on "the precise application and tissue/cell type for which the antibody will be used," and all verification data must be reported openly .

The Antibody Society specifically notes: "Each antibody must be verified based on the content of the product sheet, and subsequently through experimentation to confirm integrity, specificity and selectivity" .

How should researchers optimize Western blot protocols when using L7076 antibody?

Optimization of Western blot protocols with L7076 requires systematic adjustment of multiple parameters:

• Antibody dilution optimization: Begin with the manufacturer's recommended range (1:1,000-1:3,000 for standard ECL systems), then perform a dilution series to determine optimal concentration for your specific protein target and detection system.

• Blocking optimization: Test multiple blocking agents (5% non-fat milk, 5% BSA, commercial blocking buffers) to minimize background while preserving specific signal.

• Incubation conditions: Optimize both time and temperature:

  • Standard conditions: 1 hour at room temperature or overnight at 4°C

  • Higher dilutions may require longer incubation times

  • Evaluate signal-to-noise ratio under different conditions

• Wash procedure optimization: Insufficient washing contributes to high background, while excessive washing may reduce specific signal. A typical protocol includes:

  • 3-5 washes with TBST (TBS with 0.1% Tween-20)

  • 5-10 minutes per wash

  • Gentle agitation during washing

• Detection system matching: Different ECL substrates offer varying sensitivity levels. Select the appropriate system based on target abundance:

  • Standard ECL (SignalFire): Abundant proteins

  • Enhanced ECL (SignalFire Plus): Moderately expressed proteins

  • Ultra-sensitive ECL (SignalFire Elite): Low abundance proteins

The method of IgG purification can affect both specificity and selectivity, as noted in antibody validation literature .

What controls should be included when using L7076 in multiplexed immunoassays?

When incorporating L7076 into multiplexed immunoassays, comprehensive controls are essential:

• Primary antibody controls:

  • Single primary antibody controls to establish baseline signal

  • Isotype controls for each primary antibody species

  • Peptide competition controls to verify epitope specificity

• Secondary antibody controls:

  • Secondary-only control (L7076 without primary antibody)

  • Cross-reactivity controls with non-target primary antibodies

  • Signal spillover assessment in adjacent channels for fluorescence-based systems

• Sample-specific controls:

  • Positive and negative control samples with known target expression profiles

  • Dilution series to establish linear detection range

  • Spike-in controls with purified target proteins

• Assay design considerations:

  • When designing sandwich-type immunoassays, consider that "single epitope immunoassay" formats (where the same antibody is used for capture and detection) can compromise sensitivity due to "saturation of analyte epitopes by the probe"

  • "Several factors, including the amount of the probe, the antibody-to-label ratio, and the contact time between the probe and the analyte before reaching the capture antibody, must be adjusted"

Research on multiplex antigen lateral flow immunoassays has shown that "the positioning of the capture region along the LFIA strip was the most influent variable to increase the detectability" , suggesting spatial arrangement considerations are critical in multiplexed formats.

How can researchers address high background or non-specific binding when using L7076 antibody?

High background with L7076 can stem from multiple sources that require systematic troubleshooting:

• Blocking optimization:

  • Test alternative blocking agents (BSA vs. milk vs. commercial blockers)

  • Increase blocking time (1-2 hours at room temperature or overnight at 4°C)

  • Add blocking agent to antibody diluent (0.5-5%)

• Antibody dilution adjustment:

  • Increase dilution factor (try 1:5,000-1:10,000 for standard applications)

  • Reduce incubation time if using lower dilutions

  • Consider signal enhancement methods if higher dilutions reduce specific signal

• Washing protocol refinement:

  • Increase number of washes (5-6 washes of 5-10 minutes each)

  • Add detergent (0.1-0.3% Tween-20) to wash buffer

  • Use fresh wash buffer for each wash step

• Cross-reactivity management:

  • Pre-adsorb L7076 with tissue/cell lysate from species of interest

  • Add irrelevant immunoglobulins to block potential Fc interactions

  • Consider alternative secondary antibodies if cross-reactivity persists

• Substrate exposure optimization:

  • Reduce substrate incubation time

  • Dilute substrate if signal saturates quickly

  • Try alternative ECL substrates with different sensitivity profiles

The Antibody Society notes that "Chemical fixation and subsequent antigen retrieval, as in IHC, can affect selectivity, depending on the epitope to be detected. Hence, the antibody performance depends on the quality of sample preparation."

How should researchers interpret contradictory results when using L7076 for detection in different experimental systems?

When L7076 yields contradictory results across different experimental platforms, systematic analytical approaches are required:

• Epitope accessibility analysis:

  • Different sample preparation methods can alter epitope conformation

  • Native vs. denatured conditions affect antibody recognition

  • Post-translational modifications may mask epitopes in certain contexts

• Protocol-specific validation:

  • Re-validate antibody performance specifically for each experimental system

  • Determine optimal conditions independently for each application

  • Document protocol-specific optimization parameters

• Controls comparison:

  • Compare positive and negative controls across all experimental systems

  • Assess signal-to-noise ratios in each platform

  • Validate with alternative detection methods where possible

• Sample preparation assessment:

  • Evaluate whether differences in sample preparation affect target structure

  • Consider native vs. reducing conditions in Western blotting

  • Assess fixation effects in immunohistochemistry applications

The Antibody Society emphasizes that "The choice of antibody needs to be made strictly in the context of the type of experiments it is required for" . They further note that "The required selectivity of the antibody is not only determined by the chosen antigen and the dilution/concentration of the antibody, but also by the intended application" .

How can L7076 be utilized in studying broadly neutralizing antibodies against coronaviruses?

L7076 can play a critical role in characterizing broadly neutralizing antibodies (bNAbs) against coronaviruses through multiple experimental approaches:

• Western blot characterization of bNAbs:

  • Use L7076 as a secondary antibody to detect mouse-derived primary antibodies targeting coronavirus spike proteins

  • Quantify binding to spike proteins from different coronavirus strains

  • Assess binding to specific spike protein domains (S1, S2, RBD, NTD)

• Epitope mapping applications:

  • Detect binding of mouse antibodies to coronavirus spike protein fragments

  • Characterize fusion peptide-targeted antibodies that show broad neutralizing activity

  • Identify conserved epitopes across coronavirus species

Research has identified that "six monoclonal antibodies that bind to spike proteins from all seven human-infecting coronaviruses. All six antibodies target the conserved fusion peptide region adjacent to the S2' cleavage site" . Detection of these using mouse-derived antibodies would require secondary antibodies like L7076.

• Structural analysis support:

  • Detect bNAbs in crystallization studies to determine binding mechanisms

  • Characterize antibody-fusion peptide complexes where "the fusion peptide epitope adopts a helical structure"

  • Study structure-function relationships of broadly neutralizing antibodies

• Validation of neutralizing activity:

  • Support assays that correlate antibody binding with neutralizing function

  • Monitor antibody reactivity across coronavirus variants

  • Identify critical binding residues through mutagenesis studies

Research shows that "COV44-62 and COV44-79 broadly neutralize alpha and beta coronaviruses, including SARS-CoV-2 Omicron subvariants BA.2 and BA.4/5" , and L7076 could support detection of these antibodies in various experimental systems.

What methodological considerations are important when using L7076 to study anti-drug antibody responses in therapeutic antibody development?

When employing L7076 to study anti-drug antibody (ADA) responses during therapeutic antibody development, several advanced methodological considerations are critical:

• ADA assay design considerations:

  • Optimize bridging ELISA or ECLIA formats for ADA detection

  • Select appropriate positive and negative control samples

  • Establish cut-point determination strategies for screening, confirmation, and titration assays

• Managing drug interference:

  • Implement acid dissociation steps to release ADAs from drug complexes

  • Utilize drug-tolerant assay formats when high circulating drug levels are expected

  • Validate recovery of known ADA concentrations in the presence of therapeutic antibody

• Characterization of neutralizing capacity:

  • Develop functional cell-based assays to distinguish neutralizing from non-neutralizing ADAs

  • Correlate neutralizing activity with binding titers

  • Assess impact of neutralizing ADAs on pharmacokinetics and pharmacodynamics

In clinical studies with GSK2618960 (an anti-IL-7 receptor monoclonal antibody), researchers observed that "83% (5 of 6) of GSK261896-treated subjects in the 0.6 mg/kg cohort and 100% (all 6) of GSK261896-treated subjects in the 2.0 mg/kg cohort were confirmed positive for anti-GSK2618960 antibodies. Additionally, most subjects (64%) that confirmed positive for anti-GSK2618960 antibodies also had neutralizing activity" .

• Memory B-cell assessment:

  • Develop protocols to detect drug-specific memory B cells

  • Correlate memory B-cell development with persistent ADA responses

  • Assess long-term immunogenicity risk based on memory B-cell presence

Research found that "GSK2618960-specific memory B cells were detected in a B cell enzyme-linked immunospot assay... Memory B cell activity developed as early as day 29, and was observed in all of those subjects who had developed ADAs by day 169" .

• Validation reporting requirements:

  • Report sample preparation methods in detail

  • Document assay cut-points and their determination method

  • Specify sensitivity, drug tolerance, and precision metrics for ADA assays

How can researchers effectively utilize L7076 in developing and validating epitope-specific agglutination assays for COVID-19 antibody testing?

Developing epitope-specific agglutination assays for COVID-19 antibody testing with L7076 requires integration of several advanced methodological approaches:

• Epitope identification and selection:

  • Identify immunodominant epitopes from SARS-CoV-2 proteome using peptide microarrays

  • Select epitopes that show high sensitivity and specificity for COVID-19 diagnosis

  • Include epitopes that can differentiate between infection-induced and vaccine-induced immunity

• Agglutination assay development:

  • Conjugate selected epitope peptides to carrier particles (latex or other microspheres)

  • Optimize peptide density on carrier particles for maximum sensitivity

  • Determine critical agglutination parameters (sample dilution, reaction time, etc.)

• Variant detection considerations:

  • Incorporate epitopes containing mutations found in variants of concern

  • Design parallel assays with wild-type and variant epitopes to detect variant-specific antibodies

  • Validate with serum panels from patients infected with different SARS-CoV-2 variants

Research has shown that "epitope-resolved antibody testing not only affords a high-resolution alternative to conventional immunoassays to delineate the complex humoral immunity to SARS-CoV-2 and differentiate between neutralizing and non-neutralizing antibodies, but it also may potentially be used to predict clinical outcome" .

• L7076 application in assay validation:

  • Use L7076 to detect mouse monoclonal antibodies binding to epitope-coated surfaces

  • Employ in competitive binding assays to characterize epitope specificity

  • Apply in quality control testing of epitope presentation on carrier particles

• Mutation impact assessment:

  • Evaluate how specific mutations affect antibody recognition

  • Design assays to detect antibody escape due to mutations

For example, research on the P681H mutation showed that "while the original epitopes exhibited increased IgG binding with time, the P681H-mutant epitope did not show detectable antibody binding signal for the same plasma samples. These data indicate that the P681H mutation altered the specificity of the corresponding epitope (S-671) and rendered it unrecognizable by antibodies against the original coronavirus" .

How can L7076 contribute to the development of broadly neutralizing antibodies using phage display technology?

L7076 can significantly enhance phage display technology for broadly neutralizing antibody development through several advanced applications:

• Phage selection monitoring:

  • Detect mouse antibody fragments displayed on phage surfaces

  • Quantify enrichment of specific binders during selection rounds

  • Assess cross-reactivity of selected phages against multiple antigens

• Cross-panning strategy implementation:

  • Support detection in cross-panning experiments using "similar toxins from different snake species facilitating the discovery of antibodies with broadly neutralizing capabilities"

  • Monitor binding enrichment across heterologous targets

  • Identify conserved epitope recognition across related antigens

• Oligoclonal recombinant antivenom development:

  • Characterize individual components of oligoclonal antibody mixtures

  • Assess relative contributions of each antibody clone to neutralizing activity

  • Support quality control of recombinant antivenom preparations

• Target-specific optimization:

  • Enable detection of antibodies against "antigens with high toxicity or low immunogenicity"

  • Support assays distinguishing high-affinity from low-affinity binders

  • Facilitate deconvolution of complex antibody mixtures

Phage display technology has proven valuable for discovering broadly neutralizing antibodies, as it "enables many aspects of engineering and tailoring to individual antibody discovery campaigns" .

What role can L7076 play in benchmarking generative models for antibody design?

L7076 can serve as a critical tool in experimental validation of computationally designed antibodies from generative models:

• Binding validation of designed antibodies:

  • Detect mouse-derived framework regions in chimeric antibody designs

  • Quantify binding of designed antibodies to target antigens

  • Compare experimental affinities with computational predictions

• Structure-function correlation studies:

  • Support assays correlating structural features with binding properties

  • Validate computational predictions of antibody-antigen interactions

  • Assist in refinement of structural models based on experimental data

• Model benchmarking support:

  • Enable high-throughput screening of computationally designed antibody variants

  • Quantify success rates of different computational approaches

  • Provide experimental data for refinement of generative models

Recent research in generative models for antibody design has shown that "log-likelihood scores from these generative models correlate well with experimentally measured binding affinities, suggesting that log-likelihood can serve as a reliable metric for ranking antibody sequence designs" .

• Multi-modality model validation:

  • Support validation of sequence-structure-to-sequence models like "LM-Design and IgBlend"

  • Enable experimental testing of graph-based antibody design approaches

  • Facilitate comparison between different computational paradigms

Advanced computational methods like diffusion models have been scaled up "by training it on a large and diverse synthetic dataset, significantly enhancing its ability to predict and score binding affinities" , and L7076 can support experimental validation of these predictions.

How can L7076 be utilized in radiolabeled monoclonal antibody imaging studies?

L7076 can contribute to radiolabeled monoclonal antibody imaging research through several specialized applications:

• Pre-clinical validation of radiolabeled antibodies:

  • Detect mouse-derived domains in chimeric imaging antibodies

  • Assess preservation of binding specificity after radiolabeling

  • Quantify binding in parallel with radioactive detection methods

• Quality control of radiolabeled preparations:

  • Monitor antibody integrity following radiolabeling procedures

  • Assess potential aggregation or degradation post-labeling

  • Compare binding efficiency before and after conjugation with radioisotopes

• Biodistribution study support:

  • Complement radioactive detection with immunohistochemical analysis

  • Correlate imaging signals with antibody localization in tissues

  • Validate target expression in tissues showing radiotracer uptake

Research with radiolabeled antibodies has shown promising results, as in studies with 111In-labeled 067-213 which "showed CD73-expression-dependent tumor uptake and low uptake in normal organs and tissues" .

• Dosimetry correlation studies:

  • Support validation of radiation dose estimates based on biodistribution

  • Assist in correlating antibody concentrations with radiation exposure

  • Enable tissue-specific analysis of antibody localization

Dosimetry studies with radiolabeled antibodies provide critical safety data, as shown in research where "the estimated absorbed doses in humans were reasonably low" for 111In-labeled 067-213 antibody.